在托西利祖马布治疗期间,中国类类风湿性关节炎患者的代谢参数和血清YKL-40水平的变化
Wenlu Hu1, Yanxia Ding1, Kelei Guan2
1Department of Rheumatology and Immunology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Clinical rheumatology
|May 2, 2024
概括
在类风湿性关节炎 (RA) 患者中,托西利祖马布 (TCZ) 和甲铁酸 (MTX) 治疗增加了BMI和脂质水平,同时降低了TC/HDL-C比率和血清YKL-40 (sYKL-40). 减少sYKL-40与增加的总胆固醇相关.
科学领域:
- 类风湿病学 类风湿病学
- 代谢医学是一种代谢医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性炎症性疾病.
- 托西利祖马布 (TCZ) 和甲铁 (MTX) 是常用的 RA 疗法.
- 在接受TCZ+MTX治疗的RA患者中,代谢变化及其与YKL-40等生物标志物的关系尚未完全理解.
研究的目的:
- 为了研究TCZ和MTX治疗的非糖尿病RA患者的代谢变化.
- 在此疗法期间探索代谢参数和血清YKL-40 (sYKL-40) 水平之间的关联.
主要方法:
- 积极的,非糖尿病的RA患者耐受MTX被纳入.
- 患者每4周内接受静脉TCZ (8mg/kg),并与MTX结合24周.
- 代谢参数和sYKL-40在基线和4,12和24周被测量;使用了斯皮尔曼等级相关性.
主要成果:
- 在第24周观察到BMI,总胆固醇 (TC),HDL-C和甘油三 (TG) 的显著增加.
- 发现TC/HDL-C比率和sYKL-40水平显著下降;胰岛素耐药性没有变化.
- sYKL-40的变化与TC水平的变化有显著的负相关性 (r=-0.334,p=0.002).
结论:
- 联合TCZ和MTX治疗显著增加了RA患者的BMI和脂质水平.
- 治疗导致TC/HDL-C比率和sYKL-40水平下降.
- 在TCZ+MTX治疗期间,TC水平增加和sYKL-40水平降低之间存在显著的相关性.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134


